Milestones

2019
Benztropine Approved by Health Canada
Valeo starts trading on CSE ("CSE:VPH")
Valeo Licenses a Bio-Similar for Hospital use.
Six (6) Additional products licensed for Hospitals
Onstryv Approval by Health Canada
2018
Utrogestan Licenced from Besins Healthcare
Filing and approval of preliminary prospectus to list on CSE
Ethacrynate Sodium Approved in Canada and filed in the USA
In-licensing of 3 additional Hospital products
2017
Licensing of Onstryv from Zambon
Filing of Onstryv with Health Canada for Parkinson's disease
2016
Completed development of Ethacrynate
Sodium for Global commercialization
Licensing of Benztropine
2015
Agreement with Ethypharm to distribute M-Eslon
2014
Transition to Specialty Pharmaceutical Company by divesting Derm portfolio
Synacthen License for Canada
Launch of Baclofen
2013
Product Acquisition from Paladin Labs
Pamidronate Product Launch
2012
Veralac Product Launch
2011
Celestoderm Product Launch
2010
Vancomycin Product Launch
2009
Product Acquisition from Medicis
2008
Product Acquisition from Schering-Plough
Product Acquisition from Sandoz
2007
Aton Partnership (Merck Product Acquisition)
2005
Product Acquisition
Hydrosal Product Launch
2004
In-license Agreement
2003
Valeo Pharma founded
In-license agreement with Stiefel